Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$8.30 +3.2%	$9.48	$3.79 ▼ $23.40	$379.14M	0.59	2.04 million shs	1.32 million shs
CYRX CryoPort	$9.08 +6.9%	$7.31	$4.58 ▼ $9.66	$455.27M	1.88	539,853 shs	1.01 million shs
HUMA Humacyte	$1.78 -0.8%	$2.34	$1.15 ▼ $7.48	$276.11M	1.9	3.98 million shs	5.99 million shs
IMUX Immunic	$0.83 -2.7%	$0.85	$0.56 ▼ $2.11	$81.81M	1.39	1.24 million shs	1.39 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+2.81%	+4.82%	+5.24%	+4.82%	+105.10%
CYRX CryoPort	+4.94%	+25.96%	+12.45%	+31.22%	+8.43%
HUMA Humacyte	+2.57%	-22.29%	-22.29%	-4.01%	-72.86%
IMUX Immunic	+0.38%	-13.14%	+2.66%	-12.79%	-35.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPR Capricor Therapeutics	3.6819 of 5 stars	4.6	4.0	2.8	0.8	0.6
CYRX CryoPort	3.931 of 5 stars	4.5	2.0	2.6	3.3	1.3
HUMA Humacyte	1.6554 of 5 stars	3.5	1.0	1.7	0.8	0.6
IMUX Immunic	2.9889 of 5 stars	3.6	2.0	3.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	3.11	Buy	$22.56	171.75% Upside
CYRX CryoPort	3.00	Buy	$12.00	32.16% Upside
HUMA Humacyte	3.00	Buy	$10.64	497.91% Upside
IMUX Immunic	3.29	Buy	$7.50	804.38% Upside

Current Analyst Ratings Breakdown

Latest IMUX, CYRX, HUMA, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	HUMA Humacyte	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.50
8/12/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
8/11/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/8/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/6/2025	CYRX CryoPort	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2025	CYRX CryoPort	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Weight ➝ Overweight	$15.00
8/6/2025	CYRX CryoPort	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$16.00
7/23/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/22/2025	CYRX CryoPort	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
7/14/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $12.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$22.27M	17.02	N/A	N/A	$3.20 per share	2.59
CYRX CryoPort	$228.38M	1.99	N/A	N/A	$7.44 per share	1.22
HUMA Humacyte	$1.57M	175.87	N/A	N/A	($0.41) per share	-4.34
IMUX Immunic	N/A	N/A	N/A	N/A	$0.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$40.47M	-$1.64	N/A	N/A	N/A	-181.71%	-61.50%	-50.32%	8/13/2025 (Estimated)
CYRX CryoPort	-$114.76M	$1.33	6.83	N/A	N/A	37.21%	-10.48%	-5.56%	N/A
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-78.32%	N/A
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-461.46%	-217.16%	N/A

Latest IMUX, CYRX, HUMA, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	CAPR Capricor Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$2.60 million	N/A
8/11/2025	Q2 2025	HUMA Humacyte	-$0.15	-$0.24	-$0.09	-$0.24	$0.94 million	$0.30 million
8/7/2025	Q2 2025	IMUX Immunic	-$0.18	-$0.20	-$0.02	-$0.20	N/A	N/A
8/5/2025	Q2 2025	CYRX CryoPort	-$0.20	-$0.29	-$0.09	$2.05	$41.74 million	$45.45 million
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	6.55	6.55
CYRX CryoPort	0.51	5.56	5.24
HUMA Humacyte	0.36	3.68	3.28
IMUX Immunic	N/A	2.19	2.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
CYRX CryoPort	92.90%
HUMA Humacyte	44.71%
IMUX Immunic	51.82%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	10.50%
CYRX CryoPort	10.10%
HUMA Humacyte	5.10%
IMUX Immunic	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	101	45.68 million	40.88 million	Optionable
CYRX CryoPort	1,186	50.14 million	45.07 million	Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
IMUX Immunic	70	98.65 million	94.11 million	Optionable

IMUX, CYRX, HUMA, and CAPR Headlines

Recent News About These Companies

What is Leerink Partnrs' Estimate for Immunic Q1 Earnings?

August 12 at 4:08 AM | marketbeat.com

William Blair Predicts Immunic's Q1 Earnings (NASDAQ:IMUX)

August 12 at 4:08 AM | marketbeat.com

William Blair Forecasts Immunic's Q1 Earnings (NASDAQ:IMUX)

August 12 at 3:47 AM | americanbankingnews.com

Immunic (NASDAQ:IMUX) Announces Quarterly Earnings Results

August 11 at 11:33 AM | marketbeat.com

Immunic, Inc. (IMUX) latest stock news and headlines – Yahoo Finance

August 10 at 6:17 PM | sg.finance.yahoo.com

D. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)

August 9, 2025 | marketbeat.com

Immunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMI

August 9, 2025 | proactiveinvestors.com

Immunic (IMUX) Q2 Loss Widens 25%

August 8, 2025 | theglobeandmail.com

Immunic advances MS drug program with Phase 3 trials fully enrolled

August 7, 2025 | proactiveinvestors.com

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 7, 2025 | gurufocus.com

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | ...

August 7, 2025 | gurufocus.com

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 7, 2025 | prnewswire.com

Immunic (IMUX) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Immunic, Inc. (NASDAQ:IMUX) Receives $7.50 Average Target Price from Brokerages

August 5, 2025 | americanbankingnews.com

Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Buy" from Analysts

July 31, 2025 | marketbeat.com

Immunic (NASDAQ:IMUX) Stock Price Down 3.6% - Time to Sell?

July 29, 2025 | marketbeat.com

Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial

July 25, 2025 | msn.com

Immunic board authorizes up to 35 million stock ... - Investing.com

July 13, 2025 | investing.com

Immunic, Inc. (IMUX) Latest Stock News & Headlines - Yahoo Finance

July 9, 2025 | ca.finance.yahoo.com

Immunic CEO discusses Phase 2 multiple sclerosis study success - ICYMI

June 28, 2025 | proactiveinvestors.com

Immunic reveals long-term data supporting potential of MS drug vidofludimus calcium

June 24, 2025 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX, CYRX, HUMA, and CAPR Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$8.30 +0.26 (+3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$8.32 +0.02 (+0.30%)

As of 07:51 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

CryoPort NASDAQ:CYRX

$9.08 +0.59 (+6.95%)

Closing price 04:00 PM Eastern

Extended Trading

$8.96 -0.12 (-1.27%)

As of 07:47 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Humacyte NASDAQ:HUMA

$1.78 -0.02 (-0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$1.78 -0.01 (-0.28%)

As of 07:47 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Immunic NASDAQ:IMUX

$0.83 -0.02 (-2.69%)

Closing price 04:00 PM Eastern

Extended Trading

$0.83 +0.00 (+0.33%)

As of 07:34 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time